Description
Versavo 100 mg Injection contains Bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). By blocking VEGF, Bevacizumab prevents the formation of new blood vessels that tumors need to grow and spread.
🔬 Mechanism of Action
Bevacizumab binds to VEGF and inhibits angiogenesis (new blood vessel formation). Without an adequate blood supply, tumor growth slows and metastatic spread may be reduced.
💊 Indications
Versavo 100 mg is indicated for the treatment of:
- Metastatic Colorectal Cancer (mCRC)
- Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Breast Cancer (as per regional approvals)
- Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Cervical Cancer
- Glioblastoma (GBM)
It is commonly administered in combination with chemotherapy or other anticancer agents.
📌 Key Features of Versavo 100 mg
- Strength: 100 mg
- Dosage Form: Intravenous infusion
- Therapeutic Class: Anti-VEGF Monoclonal Antibody
- Administration: Given by IV infusion under medical supervision
- Monitoring: Blood pressure, urine protein levels, and overall clinical status must be regularly monitored
⚕️ Benefits of Bevacizumab
- Targeted anti-angiogenic therapy
- Slows tumor progression
- Enhances effectiveness when combined with chemotherapy
- Widely used in multiple advanced cancers
⚠️ Precautions
- Risk of hypertension and proteinuria
- Increased risk of bleeding or delayed wound healing
- Gastrointestinal perforation (rare but serious)
- Regular monitoring required during treatment
Versavo 100 mg (Bevacizumab Injection) offers an advanced targeted therapy option in modern oncology, helping control tumor growth and improve clinical outcomes when used as part of a comprehensive cancer treatment plan under specialist supervision.
